Members can see how their bodies respond to specific foods, medications, and daily choices
Study participants We identified all adult (aged 20 years) patients with NAFLD and type 2 diabetes who had newly started treatment with non-insulin glucose-lowering drugs (metformin, GLP-1RAs, SGLT2 inhibitors, sulfonylureas, meglitinides, thiazolidinediones, acarbose or dipeptidyl peptidase-4 inhibitors) between 1 January 2013 and 31 December 2021
doi:10.1037/0033-2909.121.1.3 Campbell MK, DeVellis BM, Strecher VJ, Ammerman AS, DeVellis RF, Sandler RS
Clinicians who broaden their diagnostic criteria and consider GLP1s within a liverfirst strategy may improve outcomes for patients who would otherwise go untreated or underdiagnosed
Because it is not peptide-based, it can survive digestion and be absorbed through the gastrointestinal tract
2021 Apr 20;12(5):413